---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059749"
form_type: "8-K"
ticker: null
cik: "0001463361"
company_name: "Unity Biotechnology, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:39:32.614048+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Unity Biotechnology Q1 net loss $5.8M, cash $38.3M; ASPIRE DME study on track

## Summary
- Net loss $5.8M for Q1 2024 vs $5.3M in Q1 2023; cash & securities $38.3M as of Mar 31, 2024.
- R&D expenses decreased to $3.7M from $5.8M due to completion of prior studies; focus on ASPIRE.
- Phase 2b ASPIRE study for UBX1325 in DME upsized to 50 patients, extended to 36 weeks; 24-week data expected Q1 2025, 36-week data Q2 2025.
- Cash runway sufficient into Q3 2025.

## SEC filing metadata
- accession: 0000950170-24-059749
- form_type: 8-K
- cik: 0001463361
- company_name: Unity Biotechnology, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1463361/000095017024059749/0000950170-24-059749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1463361/000095017024059749/ubx-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059749
- JSON: https://secwatch.observer/filing/0000950170-24-059749.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059749.txt

## Key facts
- Earnings Releases
  Unity Biotechnology, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1463361/000095017024059749/0000950170-24-059749-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.